Ardelyx

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 267

Market Cap: $1.4B

Website: http://www.ardelyx.com

Introduction: Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Clinical Trials

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RDX5791
Drug: Placebo

First Posted Date: 2016-06-30

Last Posted Date: 2016-06-30

Lead Sponsor: Ardelyx

Target Recruit Count: 80

Registration Number: NCT02819687

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: RDX5791
Drug: Placebo

First Posted Date: 2016-06-10

Last Posted Date: 2016-06-10

Lead Sponsor: Ardelyx

Target Recruit Count: 105

Registration Number: NCT02796131

A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C

Phase 3

Completed

Conditions: Constipation Predominant Irritable Bowel Syndrome

Interventions: Drug: Tenapanor

First Posted Date: 2016-04-05

Last Posted Date: 2020-09-09

Lead Sponsor: Ardelyx

Target Recruit Count: 312

Registration Number: NCT02727751

Locations: 🇺🇸
Ardelyx Clinical Site, Miami, Florida, United States

A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C

Phase 3

Completed

Conditions: Constipation Predominant Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Tenapanor

First Posted Date: 2016-02-19

Last Posted Date: 2020-04-22

Lead Sponsor: Ardelyx

Target Recruit Count: 593

Registration Number: NCT02686138

Locations: 🇺🇸
Ardelyx Investigative Site 257, Dothan, Alabama, United States
🇺🇸
Ardelyx Investigative Site 288, Miami, Florida, United States
🇺🇸
Ardelyx Investigative Site 138, Atlanta, Georgia, United States

and more 113 locations

An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

Phase 3

Completed

Conditions: Hyperphosphatemia

Interventions: Drug: Tenapanor
Drug: Placebo

First Posted Date: 2016-02-05

Last Posted Date: 2020-08-10

Lead Sponsor: Ardelyx

Target Recruit Count: 219

Registration Number: NCT02675998

Locations: 🇺🇸
Ardelyx Investigative Site 409, Brookhaven, Mississippi, United States
🇺🇸
Ardelyx Investigative Site 402, Kalamazoo, Michigan, United States
🇺🇸
Ardelyx Investigative Site 401, Saint George, Utah, United States

and more 29 locations

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

Phase 3

Completed

Conditions: Constipation Predominant Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Tenapanor

First Posted Date: 2015-12-04

Last Posted Date: 2020-04-21

Lead Sponsor: Ardelyx

Target Recruit Count: 606

Registration Number: NCT02621892

Locations: 🇺🇸
Ardelyx Investigative Site 137, Norcross, Georgia, United States
🇺🇸
Ardelyx Investigative Site 278, Hagerstown, Maryland, United States
🇺🇸
Ardelyx Investigative Site 135, Boston, Massachusetts, United States

and more 108 locations